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CC BY-NC-ND license (http://creativeBackground: Advances in multidisciplinary care for pediatric cancer have resulted in significant
improvement in cure rates over the last decades; however, these advances have not been uni-
form across all age groups. Cancer is an important cause of perinatal mortality, yet the full
spectrum of malignant neoplasms in newborns is not well defined.
Methods: The authors have reviewed the clinical features and outcomes of 37 newborns with
congenital malignant tumors treated at three referral centers in North, Central, and South
Poland between 1980 and 2014. Event-free survival (EFS) and overall survival (OS) rates were
estimated by KaplaneMeier methods and compared using long-rank test and Cox models.
Results: Twenty-two patients were diagnosed prenatally. The most common diagnoses were
neuroblastoma (48.7%), followed by malignant germ-cell tumor (16.2%), and Wilms’ tumor
(8.1%). Neuroblastoma was the most common malignancy among full-term infants, and malig-
nant sacrococcygeal teratoma was the most common malignancy in premature infants. Thirtyof Surgical Oncology for Children and Youth, Institute of Mother and Child, Ulica Kasprzaka 17a, 01-
oga.pl (A. Raciborska).
015.08.007
Pediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
296 A. Raciborska et alpatients (81%) are alive with a median follow-up of 4.8 years from diagnosis. Patients with
Wilms’ tumor and malignant germ-cell tumors had the best outcomes (5-year OS 100% for
both), whereas the worst prognosis was observed for sarcoma patients (5-year OS 72.92%). Pre-
mature infants had better outcome than full-term infants (5-year OS 92.8% vs. 72.58%, respec-
tively).
Conclusion: Although rare, neonatal cancers can present with an aggressive clinical behavior,
but they have a generally good outcome. Early diagnosis and management by expert multidis-
ciplinary teams that integrate perinatal medicine experts with pediatric and surgical oncolo-
gists are critical. Centralized care with clear referral pathways that facilitate early
initiation of specialized treatment should be prioritized.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Cancer in newborns is rare, with an estimated incidence of
3.65/100,000 live births. Although most neonatal neo-
plasms are considered to have a benign behavior, malignant
tumors represent a significant cause of perinatal mortal-
ity,1e3 which may be related to obstetric or postnatal sur-
gical complications, or disease progression.4 With advances
in obstetrical and perinatal care, including fetal imaging,
an increasing proportion of these tumors can be identified
prenatally, thus allowing for proper planning for delivery
and postnatal care.5 The prognosis is related to the tumor
behavior, which may differ significantly between the peri-
natal period and later ages, suggesting a role for develop-
mental biology factors.1,6
The care of newborns with malignant neoplasms requires
a state-of-the-art multidisciplinary team that integrates
the specialists involved in the care of high-risk pregnancies
and newborns with pediatric oncology experts.5 Herein, we
report the experience of three centers providing multidis-
ciplinary care for congenital malignant tumors in premature
and neonatal patients in Poland.
2. Materials and methods
2.1. Patients and treatment
This retrospective study included 38 patients with perinatal
malignant neoplasms (excluding mature teratomas) treated
at three Pediatric Oncology Centers in Poland during the
period 1980e2014 (Mother and Child Institute in Warsaw,
Central Poland; Wrocław Medical University in Wrocław,
South Poland; and Collegium Medicum, Nicolaus Copernicus
University, in Bydgoszcz, North Poland). Treatment was
conducted according to the existing disease-specific pro-
tocols and treatment guidelines, and it included a “watch-
and-wait” approach, or different combinations of surgery,
chemotherapy, and radiation therapy. All patients had
standard imaging and histological procedures for diagnosis,
staging, and follow-up. In the case of a prenatal diagnosis,
fetal ultrasound (US) and magnetic resonance imaging (MRI)
were performed as clinically indicated. “Total resection”
was defined as a complete resection of the tumor withoutmacroscopic or microscopic residue, “gross resection” was
defined as resulting in microscopic residue, and “subtotal
resection” was defined as resulting in macroscopic residual
disease. Approval for this retrospective study was obtained
from all the relevant institutions in compliance with in-
ternational regulations for protection of human research
subjects.
2.2. Statistical methods
Overall survival (OS) was defined as the time interval from
the date of diagnosis to the date of death or last follow-up.
Event-free survival (EFS) was defined as the time interval
from the date of diagnosis to the date of disease progres-
sion, recurrence, second malignancy, death, or date of last
follow-up for patients without events. Results distributions
were estimated using the KaplaneMeier method. Factors
were examined as predictors of OS using log-rang test.
Values of p  0.05 were considered significant. Statistical
analysis was performed using STATISTICA 10.0 for Windows
(StatSoft Inc., Tulsa, OK, USA).
3. Results
3.1. Patient characteristics and treatment
Between 1980 and 2014, 37 patients with congenital ma-
lignant neoplasms (mature and immature teratomas were
excluded) were referred for treatment to the three
oncology centers. The clinical and treatment characteris-
tics are shown in Tables 1 and 2. The median gestational
age at the time of delivery was 38 weeks (range
30e41 weeks); 14 patients (37.8%) were born preterm
(<38 weeks). Four children were very low birth weight,
born at 30e34 weeks of gestational age; three were low
birth weight, born at 34e35 weeks of gestational age, one
baby was hypertrophic, born at 35 weeks of gestational
age, and the others were eutrophic newborns. All 21 cases
diagnosed prenatally through standard screening US imag-
ing were monitored weekly by US or MRI as clinically indi-
cated, and an elective cesarean section was performed in
20 women due to rapid tumor growth (11 of them were
premature births). Ten cases (out of 14) of preterm labor
Table 1 Patients’ characteristics (n Z 37).
Characteristics n (%)
Sex
Male 20 (54)
Female 19 (46)
Gestational age
<38 wk 14 (37.8)
38 wk 23 (62.2)
Diagnosis
Neuroblastoma 18 (48.7)
Germ-cell tumor 6 (16.2)
Wilms’ tumor 3 (8.1)
Hemangiopericytoma 2 (5.4)
Infantile fibrosarcoma 2 (5.4)
Ewing’s sarcoma 2 (5.4)
Brain tumor 1 (2.7)
Hepatoblastoma 1 (2.7)
Malignant mesenchymoma 1 (2.7)
Rhabdoid tumor 1 (2.7)
Stage of disease
Metastatic 14 (37.8)
Localized 23 (62.2)
Median age at initial treatment (d) 4 (range 1e26)
Treatment
Watch and wait 1 (2.7)
Surgery alone 13 (35.2)
Surgery þ CHT 17 (45.9)
Surgery þ CHT þ RT 2 (5.4)
Surgery þ CHT þ RT þ HSCT 1 (2.7)
CHT only 2 (5.4)
Refusal 1 (2.7)
Type of surgical procedure
Biopsy 1 (3)
Gross resection 8 (24.2)
Subtotal resection 8 (24.2)
Total resection 16 (48.6)
Outcome
Alive 30 (81)
Deceased 7 (29)
CHT Z chemotherapy; HSCT Z hematopoietic stem cell
transplant; RT Z radiation therapy.
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cases were caused by the tumor (3 cases also had poly-
hydramnios), which implied preterm premature rupture of
membranes; and in four cases the reason for preterm labor
was not documented. The 16 children diagnosed post-
natally were referred after detection of the tumor during
standard neonatal evaluations by the primary care
providers.
The most common diagnosis was neuroblastoma (48.7%),
followed by malignant germ-cell tumor (mature and
immature teratomas were excluded; 16.2%) and Wilms’
tumor (8.1%). Of the 14 patients with metastatic disease,
13 (92.8%) had neuroblastoma. There were differences in
diagnosis between premature and full-term infants; neu-
roblastoma was the most common malignancy among full-
terms, and malignant sacrococcygeal tumors were the most
common malignancy in premature infants. Twenty-onepatients were diagnosed prenatally, 20 of whom were
delivered via cesarean section.
All 18 neuroblastoma cases had an abdominal primary
tumor. Five patients had International Neuroblastoma
Staging System Stages I/II, four patients had Stage IV, and
nine patients had Stage IVs (among thirteen metastatic’s
patients 7 patients had metastases to the liver, 4 to the skin
and liver, 1 only to the skin, and 1 to the skin, liver, and
bone marrow). MYCN status was evaluated in all cases and
was found to be amplified in three cases. MYCN amplifica-
tion was defined as more than fourfold increase in signal
relative to the number of chromosome 2 by fluorescence in-
situ hybridization. Initial treatment included observation
only for six patients, although chemotherapy was eventu-
ally administered to five of them due to progression. Seven
patients were treated with surgery only, and eight had
surgery and additional therapies (Table 1). Only seven of
the 15 patients with neuroblastoma (46.7%) undergoing
surgery achieved negative resection margins. Two patients
with Stage IV were treated with chemotherapy only and
died of disease progression. Three patients (2 Stage IVs and
1 Stage IV) underwent radiation therapy due to progression
of liver metastases. The four patients with Stage IV disease
were treated with intensive platinum-based regimens, and
one patient received consolidation with high-dose chemo-
therapy and autologous hematopoietic stem cell transplant
for MYCN-amplified disease. Of the three patients with
MYCN-amplified disease, two died of disease progression
and one is alive after receiving high-dose chemotherapy
and autologous transplant. None of the patients received
cis-retinoic acid or anti-GD2 therapy. Fourteen patients
with neonatal neuroblastoma (77.8%) are alive with a me-
dian follow-up of 3.8 years from diagnosis (range
0.1e18.8 years). Three patients (2 Stage IV and 1 Stage II)
died of disease progression, and one patient with Stage I
died from postsurgical complications.
Of the six patients with a malignant germ-cell tumor,
five had a sacrococcygeal primary tumor and one had a
head and neck tumor; all had mixed GCTwith component of
yolk sac tumor histology. A complete resection was ach-
ieved in all cases; two of them had positive margins, and
one relapsed and subsequently received chemotherapy
(Table 1). In all cases, the alpha-fetoprotein levels were
elevated for age at the time of diagnosis, but these
declined appropriately and normalized after surgery. All six
patients are alive with a median follow-up of 4.7 years from
diagnosis (range 0.9e11.5 years).
All three patients with Wilms’ tumor had localized dis-
ease at diagnosis, and one of them presented with hydrops
fetalis. All three patients were treated with upfront sur-
gery; two of them received adjuvant chemotherapy (1 for
intermediate-risk histology and 1 for positive margins;
Table 1). All patients are alive with a median follow-up of
1.3 years from diagnosis (range 0.5e6.8 years).
Eight patients were diagnosed with a congenital sar-
coma. This group included two patients with hemangio-
pericytoma, one in the face and one in a limb; two with
infantile fibrosarcoma of the limbs; two with Ewing’s sar-
coma, one in the face and one in a limb; one with an intra-
abdominal malignant mesenchymoma; and one with ma-
lignant rhabdoid tumor of the kidney. Seven patients had
localized disease at the time of diagnosis, and one patient
Table 2 Patient characteristics and outcome by diagnosis.
Diagnosis N Stage Median gestational
age, wk (range)
Time of tumor
detection
prenatal/
postnatal
Median age
at treatment,
d (range)
Outcome Follow up in
years (range)
Neuroblastoma 18 I/II (5 pts)
IV (4 pts)
IVs (9 pts)
38 (36e41) 2 (Stage IVs)/16 6 (1e25) DOD 3
(Stage IV 2 pts,
Stage I/II 1 pts)
TRM 1
(Stage I/II 1 pts)
NED 14
3.8 (0.01e18.8)
Germ-cell tumor 6 6 L 36 (30e38) 5/1 2.5 (1e5) NED 6 4.7 (0.9e11.5)
Wilms’ tumor 3 3 L 37 (32e40) 2/1 5 (3e26) NED 3 1.3 (0.5e6.8)
Hemangiopericytoma 2 1 L
1 M
34 (31e37) 2/0 1.5 (1e2) NED 2 5.9 (0.1e11.7)
Infantile
fibrosarcoma
2 2 L 40 (40e40) 0/2 9 (2e16) NED 2 5.4 (1.4e9.4)
Ewing’s sarcoma 2 2 L 38.5 (37e40) 1/1 14.5 (9e20) DOD 1
NED 1
1.53 (0.1e2.9)
Brain tumor 1 L 34 1/0 Refusal DOD 0.01
Hepatoblastoma 1 L 37 1/0 5 NED 0.5
Malignant
mesenchymoma
1 L 40 0/1 1 NED 8.6
Rhabdoid tumor 1 L 38 0/1 3 DOD 0.5
DOD Z dead of disease; L Z localized; M Z metastatic; NED Z no evidence of disease; pts Z patients; TRM Z treatment-related
mortality.
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and-wait approach was adopted for two patients (1 infan-
tile fibrosarcoma and 1 hemangiopericytoma), although
both progressed and required surgery and chemotherapy.
Only two of the eight patients with sarcoma (25%) under-
going surgery achieved negative resection margins. Six pa-
tients (75%) are alive with a median follow-up of 2.1 years
from diagnosis (range 0.1e11.7 years). Two patients (1
patient with rhabdoid tumor and 1 patient with Ewing’s
sarcoma) died of disease progression.
One patient with hepatoblastoma was successfully
treated with upfront chemotherapy, followed by complete
resection, and for a primary brain tumor patient with
radiological characteristics of supratentorial primitive
neuroectodermal tumor (PNET), treatment was refused by
the parents. This patient died within 1 week.
Overall, local control was performed in 33 patients
(89.1%); in 13 patients (35.1%) as the only treatment, in 17
patients (45.9%) in combination with chemotherapy, in two
patients in combination with chemotherapy and radiation
therapy (5.4%), and in one patient in combination with
chemotherapy, radiation therapy, and hematopoietic stem
cell transplant (2.7%). Only 16 of the 33 patients (48.5%)
undergoing surgery achieved negative resection margins.
Only one patient with neonatal neuroblastoma had a
spontaneous regression.
Complications in the premature babies can been divided
into those resulting from preterm delivery and those caused
by the tumor. Complications during delivery and postnatal
period included respiratory insufficiency requiring oxygen
supplementation for a group of infants, and administration
of surfactant in two cases. Thirteen critically ill children(prematurity, upper and lower airway obstruction, and
tract and abdominal compartment syndrome) required
intubation and mechanical ventilation. One patient had
hemodynamic instability caused by a highly vascularized
large tumor (hemangiopericytoma), another patient had
disruption of vascular flow to the lower extremities due to
abnormal fetal placement (germ-cell tumor), and one pa-
tient presented hydrops fetalis (Wilms’ tumor). Only one
patient died due to multiple organ failure after surgery
(neuroblastoma). Complications among term babies
included one occurrence of pneumothorax (neuroblas-
toma), and three cases of secondary infections (2 neuro-
blastomas and 1 PNET).3.2. Follow-up and outcome
Twelve patients (32.4%) had disease progression or relapse.
Thirty patients (81%) are alive with a median follow-up of
4.8 years from diagnosis (range 0.1e18.8 years). The 5-year
EFS and OS estimates were 61% and 80.38%, respectively
(Figure 1). Patients with Wilms’ tumor and germ-cell tu-
mors had the best outcome, and the worst prognosis was
observed in patients with sarcoma. The outcome for pa-
tients with neuroblastoma was not significantly different
from all other patients (data not shown). Premature infants
did better than full-term babies, although differences were
not statistically significant. The 5-year EFS and OS esti-
mates for premature infants were 77.9% and 92.8%,
respectively, compared with 50.72% and 72.58% for full-
terms, respectively. On univariate analysis, neither
Figure 1 KaplaneMeier curve of overall survival (OS) and event-free survival (EFS) for the study group.
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to have prognostic significance (Table 3).
4. Discussion
Neonatal cancers are defined by their occurrence in an in-
fant in the first 28 days after birth, or up to 44 weeks of
gestational age in the case of preterm babies.3 Our series
confirms the previously published data, highlighting the
fact that neonatal tumors differ in distribution from those
occurring later in life. Solid malignancies account for
approximately 75% of neonatal cancers, and given their
rarity, their incidence patterns and outcomes are not well
described.1e5 For many of these tumors, such as low-riskTable 3 Univariate analysis of prognostic factors using
log-rank test (n Z 37).
N 5-yr OS
(%)
p 5-yr EFS
(%)
p
Gestational age
<38 wk 13 92.8 0.171 77.9 0.061
38 wk 23 72.58 50.72
Surgical margins
Positive 17 94.11 0.263 55.21 0.263
Negative 16 80.3 76.98
Histology
Neuroblastoma 18 76.76 NS 55.11 NS
Germ-cell tumor 6 100 60
Sarcoma 8 72.92 58.34
Wilms’ tumor 3 100 100
EFS Z event-free survival; NS Z not significant; OS Z overall
survival.neuroblastoma or sacrococcygeal teratomas, outcomes
have been described to be excellent; however, neonatal
neoplasms often have a very aggressive clinical presenta-
tion that may precipitate rapid clinical deterioration of
these vulnerable infants.1,2,7e15 Complications during de-
livery or in the immediate newborn period due to the
involvement of critical organs may result in significant
morbidity and mortality unless a rapid diagnosis and plan of
care is established. It is for this reason that it is of extreme
importance to centralize care in experienced centers
where multidisciplinary treatment is available. In our se-
ries, the patients seen at three referral centers represent
half of the expected cases in Poland, highlighting the suc-
cess in implementing this referral model. Furthermore, the
low incidence of postnatal complications in our series
further supports the need to implement referral networks.
Complications during delivery and the immediate post-
natal period were relatively low; only two patients required
administration of surfactant due to respiratory distress, a
complication that needs to be anticipated in these in-
fants.14 Some children had oxygen administered because of
prematurity and it was not conditioned by the tumor. In
addition, caution should be exercised with regard to pre-
natal occurrence of Wilms’ tumor, as infants may present
with hydrops fetalis as did one of our cases.2,11 It should be
emphasized that a large-size tumor can disturb circulation
and may also be the cause of local ischemia or as well as
general circulatory disturbances, as was the case in two of
our patients. Other complications reported in newborns
with cancer include polyhydramnios, hypertension, or hy-
percalcemia.11,16,17 In our series, polyhydramnios was the
cause of cesarean section in three cases.
While our series is consistent with other published data,
we contribute valuable information about the importance
of dedicated multidisciplinary care for this vulnerable
300 A. Raciborska et alpopulation. Between 1980 and 1999, only four newborn
infants were referred to the three tertiary centers,
whereas after 2000, thanks to the cooperation of gynecol-
ogists, obstetricians, surgeons, and oncologists, we imple-
mented a referral system and more than 30 children were
referred, with a significantly improved outcome.
Germ-cell tumors and neuroblastoma are the most
common malignant solid neoplasms in the newborn period,
followed by soft-tissue sarcoma, renal tumors, brain tu-
mors, and leukemia.3,13,16,18 This distribution was
confirmed in our series, although we had a higher propor-
tion of neuroblastomas, probably resulting from the
exclusion of mature and immature teratomas. Brain and
hematologic malignancies are also underrepresented in our
series, owing to the established referral patterns in Poland.
Importantly, our series shows that although neonatal
tumors present as rapidly growing neoplasms, their ulti-
mate behavior differs from their older counterparts,
accounted by differences in biology. This is exemplified by
the distinct clinical course of neuroblastoma during in-
fancy; more than 70% of our cases had metastatic disease,
and yet their outcome was excellent. This is a well-known
phenomenon for Stage IVs neuroblastoma; however, expert
management of those patients is critical because rapidly
enlarging liver metastases may result in significant respi-
ratory and hemodynamic compromise.8,10 A similar phe-
nomenon is seen in infantile sarcomas, such as
hemangiopericytoma and fibrosarcoma; these high-grade
sarcomas are known to present with very aggressive and
rapidly growing soft-tissue masses that have often been
treated with radical, mutilating surgeries.6,7,9 However,
infantile hemangiopericytoma, like infantile fibrosarcoma,
is characterized by better clinical behavior, with docu-
mented chemoresponsiveness and spontaneous regression,
and it requires a more conservative surgical approach.6,7,19
This was confirmed in our series, where three of four chil-
dren were successfully treated with subtotal surgery and
chemotherapy. Again, early recognition and rapid referral
to an expert center is necessary to provide risk-adapted
therapies and minimize long-term, irreversible organ dam-
age. By contrast, other sarcomas such as Ewing’s sarcoma
and rhabdoid tumors do have a more aggressive behavior
necessitating intensive multidisciplinary sarcoma
treatments.6,20
Our report also underlines the importance of selecting a
conservative surgical approach. While complete surgical
resection of these tumors is the mainstay of treatment,
efforts must be made to avoid the use of radical and
mutilating procedures. In our series, more than half of the
patients undergoing surgery had positive resection margins;
this is commonly associated with a very high risk of relapse
in solid tumor oncology, yet only two patients in this group
died of disease. This highlights the importance of selecting
the most appropriate surgical approach based on the
knowledge of the natural history of each malignancy; a
conservative, nonradical approach is appropriate for in-
fantile fibrosarcoma, infantile hemangiopericytoma, and
neuroblastoma,6,7,9,10 whereas a more radical procedure is
required for most renal, brain, and liver tumors, as well as
other sarcomas.11,12,21,22
In summary, neonatal solid tumors represent a small
group of malignancies that typically present with anaggressive clinical behavior; however, their outcome is
generally favorable, owing to their unique biological fea-
tures. Early diagnosis and management by expert multi-
disciplinary teams that integrate perinatal medicine
experts with pediatric and surgical oncologists with
knowledge of the natural history of each disease are critical
for the outcome of these patients. Centralized care with
clear referral pathways that facilitate early initiation of
specialized care should be implemented.
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